期刊文献+

抗人卵巢癌×抗人CD3×抗CD28V_H单链三特异抗体的胞内可溶表达、纯化及体外活性测定 被引量:1

Soluble expression, purification and bioactivity assay of anti-ovarian carcinoma×anti-CD3×anti-CD28V_H single chain trispecific antibody
原文传递
导出
摘要 目的 研究抗人卵巢癌 (ovariancarcinoma ,oc)×抗人CD3×抗CD2 8VH 单链三特异抗体(singlechaintrispecificantibody,scTsAb)在大肠杆菌中的可溶表达与纯化及纯化后产物的活性测定 ,从而为其应用于卵巢癌治疗的临床研究打下基础。方法 将已构建的scTsAb表达载体转化大肠杆菌BL2 1(DE3)Star菌株 ,采用低温 (30℃ )、低剂量IPTG(0 .2mmol L)诱导 ,进行胞内可溶表达。根据抗卵巢癌三特异抗体 (ocTsAb)等电点较高 (pI9.0 ) ,而菌体蛋白大多为酸性蛋白的特点 ,利用DEAE弱阴离子交换层析(pH8.0 )进行一步纯化 ,并利用ELISA及FACS的方法检测纯化后抗卵巢癌三特异抗体的活性。结果 (1)SDS PAGE鉴定低温诱导时可溶比例达到 5 6 %。 (2 )绝大多数菌体蛋白被DEAE层析柱吸附 ,而抗卵巢癌三特异抗体在穿透液中流出 ,SDS PAGE检测纯度达到 90 %。 (3)ELISA结果显示纯化后的抗卵巢癌三特异抗体与重组CD2 8纯抗原 ,Jurkat(CD3+ )细胞膜提取抗原 ,SKOV3细胞膜提取抗原均有特异性结合。 (4 )FACS结果证明纯化后的抗卵巢癌三特异抗体与Jurkat(CD3+ )活细胞、SKOV3活细胞有特异性结合。结论 低温诱导胞内可溶表达的抗人卵巢癌×抗人CD3×抗CD2 8VH 单链三特异抗体经弱阴离子交换层析一步纯化后仍保持原有免疫学活性 。 Objective To investigate the soluble expression and to purify a recombinant multifunctional single chain trispecific antibody (scTsAb) which contains anti-ovarian carcinoma(oc) scFv, anti-CD3 scFv and V H domain of anti-CD28 antibody and in vitro bioactivity of the purified scTsAb. Methods The plasmid of scTsAb was transformed into E.coli strain BL21(DE3) Star. The scTsAb was over-expressed as a soluble protein when the E.coli was induced in a low concentration of IPTG (0.2mmol/L) and cultured at a low temperature (30℃). The scTsAb was purified by DEAE anion exchange chromatography. ELISA and FACS mensurate in vitro bioactivity of the purified scTsAb. Results (1) The soluble expression ratio is about 56%. (2) The scTsAb flow through DEAE chromatography and the purity is over 90%. (3) The purified scTsAb shows strong binding activities to the antigen of ovarian carcinoma cells, recombinant CD28 pure antigen and to CD3 molecules on Jurkat cells. (4) The purified antibody tightly binds to Jurkat cells and SKOV3 cells. Conclusion The soluble scTsAb maintaines its inherent bioactivity after purification by DEAE anion exchange chromatography. These results provide a technical guarantee to produce abundant sample for further bioactivity experiments and in vivo experiments. They also provide the reference standard for expression, purification and production of similar genetical engineered antibodies.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2004年第6期475-479,共5页 Chinese Journal of Microbiology and Immunology
基金 国家 8 63高科技研究发展计划基金资助项目( 2 0 0 1AA2 15 3 81)
关键词 抗人卵巢癌 抗人CD3 抗CD28VH 三特异抗体 基因表达 体外活性 scTsAb 肿瘤 Single chain trispecific antibody (scTsAb) Ovarian carcinoma CD3 CD28 Low temperature Soluble expression
  • 相关文献

参考文献3

二级参考文献44

  • 1刘喜富,萧飒,顾征,王勇,陈艾,林晴,张卫国,黄华梁,孙健,陈润生,沈倍奋,陈兴.抗人CD3单链抗体与改形单域抗体的表达[J].中国科学(C辑),1996,26(5):428-435. 被引量:7
  • 2GilBoa E. How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother, 1999, 48(7):382-385.
  • 3Zhu Z, Lewis GD, Carter P. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab') 2 for efficient lysis of p185HER2 overexpressing tumor cells. Int J Cancer, 1995, 62(3):319-324.
  • 4Kroesen BJ, ter Haar A, Spakman H, Willemse P, Sleijfer DT, de Vries EG, Mulder NH et al. Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother, 1993, 37(6):400-407.
  • 5Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk I, Repp r, Deo YM et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood, 1997, 90(11):4485-4492.
  • 6Segal DM, Weiner GJ, Weiner LM. Introduction: Bispecific antibodies. J Immunol Methods, 2001, 248(1-2):1-6.
  • 7Salomon B, Bluestone JA. Complexities of CD28/BT: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol, 2001, 19:225-252.
  • 8Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol, 2002, 2(2):116-126.
  • 9Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, liu QH, Wolf J et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res, 1999,59(12):2909-2916.
  • 10Grosse-Hovest L, Brandl M, Dohlsten M, Kalland T, Wilmanns W, Jung G. Tumor-growth hahibition with bispecific antibody fragments in a syngeneic mouse melanoma model: The role of targeted T-cell co-stimulation via CD28. Int J Cancer, 1999, 80(1):138-144.

共引文献7

同被引文献22

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部